Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Qingling Motors Co., Ltd. (QIN.F) Follow Compare 0.0622 +0.0012 +(1.97%) As of 8:13:15 AM GMT+1. Market Open. Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for QIN.F 1D 5D -3.72% 1M 4.01% 3M -4.31% 6M 18.70% YTD 0.32% 1Y -14.56% 5Y -63.41% All -48.17% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Related News View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Monday; Intuitive Machines, Robinhood Markets to Decline Top India Drugmaker to Buy US-Based Checkpoint for $355 Million Rivian Is Living Up to Its Promises. Is This Top EV Stock Worth the Risk? Futures lower as tariff worries continue; Tesla falls DoorDash, TKO, Williams-Sonoma To Join S&P 500. AppLovin Snubbed Again. Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial Tesla’s stock defied gravity for years. Is Elon Musk’s EV party over? Beam Therapeutics Announces Pricing of Underwritten Offering Elon Musk's feud with OpenAI CEO Sam Altman, explained Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation Tesla Stock Falls Again. Why Musk DOGE Fears May Continue to Eclipse AI Hope.